庞继景教授指出，基因检测正逐步成为儿童视力评估常规项目，结合屈光矫正形成多维度干预体系。这 种转变使弱视治疗成功率提升30%，并为遗传性眼病患者抢抓3-12岁视觉发育黄金期。 作为国内眼健康全产业链平台，何氏眼科持续深耕基因治疗、干细胞再生医学及智能设备数据应用三大 领域。在"十四五"眼健康规划推动下，企业正通过科技创新践行"智慧光明城"战略目标，为健康中国建 设注入新动能。（燕云） （文章来源：证券时报网） 近日，何氏眼科(301103)在儿童弱视诊疗领域取得突破性进展。通过融合基因检测与视知觉学习训练技 术，成功将传统弱视诊疗模式推向精准化新阶段。 在临床实践中，遗传眼病首席科学家庞继景教授团队接诊的9岁高度近视患儿案例引发关注。通过 OPN1LW基因检测，团队发现其近视实为遗传性视网膜疾病早期表现，颠覆了传统"弱视"诊断结论。基 于此，团队创新采用视知觉学习训练：通过Gabor视标刺激视觉皮层神经可塑性，经4个月家庭化训练， 患儿右眼视力从0.7提升至0.9，屈光度发展得到有效控制。 这项技术的突破性在于构建"基因筛查-大脑重塑"双轨诊疗体系。通过排除致病基因变异确保诊断精准 性，再运用视知觉训练激活视 ...

Core Viewpoint - The company, Liaoning He Eye Hospital Group Co., Ltd., has announced its 2024 annual equity distribution plan, which includes a cash dividend of 1.5 RMB per 10 shares for all shareholders, excluding repurchased shares [2][6]. Summary by Sections Equity Distribution Plan - The total number of shares eligible for the cash dividend is 155,303,752 shares after excluding 2,722,719 shares held in the repurchase account [2][6]. - The total cash dividend amount to be distributed is 23,295,562.80 RMB (including tax) [2][6]. Dividend Calculation - The cash dividend per share, after considering the total share capital including repurchased shares, is calculated as 1.474155 RMB per share [2][11]. - The reference price for ex-dividend trading will be adjusted by subtracting the cash dividend per share from the closing price on the last trading day before the ex-dividend date [2][11]. Shareholder Meeting Approval - The equity distribution plan was approved at the shareholder meeting held on May 22, 2025, and the implementation will occur within two months of this approval [4][5]. Key Dates - The record date for the equity distribution is set for May 30, 2025, and the ex-dividend date is June 3, 2025 [7]. Eligible Shareholders - The distribution will be made to all shareholders registered with the China Securities Depository and Clearing Corporation Limited, Shenzhen Branch, as of the record date [8]. Repurchased Shares - Shares held in the company's repurchase account will not participate in this equity distribution [9].

Core Viewpoint - The company has announced its 2024 annual profit distribution plan, which includes a cash dividend of 1.5 RMB per 10 shares for all shareholders, excluding repurchased shares [1][2]. Group 1: Dividend Distribution Details - The total number of shares eligible for the cash dividend is 155,303,752 shares after excluding 2,722,719 repurchased shares, resulting in a total cash dividend payout of 23,295,562.80 RMB (including tax) [1][2]. - The cash dividend per share, calculated based on the total share capital, is approximately 1.474155 RMB per share [1][4]. - The dividend distribution will not include capital reserve transfers to increase share capital or stock bonuses [2][3]. Group 2: Key Dates - The record date for the dividend distribution is set for May 30, 2025, and the ex-dividend date is June 3, 2025 [2][3]. Group 3: Taxation and Adjustments - The company will not withhold individual income tax for certain shareholders, with tax obligations calculated based on the holding period upon stock transfer [2][4]. - The reference price for the ex-dividend will be adjusted by subtracting the cash dividend per share from the closing price on the last trading day before the ex-dividend date [4].

2024 年年度权益分派实施公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 特别提示： 1、辽宁何氏眼科医院集团股份有限公司（以下简称"公司"）回购专用证券 账户中的股份 2,722,719 股不参与本次权益分派。本次分红派息将以公司现有总 股本 158,026,471 股剔除已回购股份 2,722,719 股后的 155,303,752 股为基数，向 全体股东每 10 股派发现金红利 1.5 元（含税），实际派发现金分红总额 =155,303,752 股×1.5 元/10 股=23,295,562.80 元（含税），不进行公积金转增股本 和送红股。 2、本次权益分派实施后计算除权除息价格时，按公司总股本（含回购股份） 折算的每 10 股现金分红（含税）=现金分红总额÷总股本（含回购股份）×10 股 =23,295,562.80 元÷158,026,471 股×10 股=1.474155 元/股（保留六位小数，最后一 位直接截取，不四舍五入）。 本次权益分派实施后除权除息参考价=除权除息日前一交易日收盘价-按公 司总股本折算的每股现金分红=除权除息日前一 ...

北京市中伦律师事务所 法律意见书 二〇二五年五月 法律意见书 关于辽宁何氏眼科医院集团股份有限公司 2024 年年度股东大会的 北京市中伦律师事务所 关于辽宁何氏眼科医院集团股份有限公司 2024 年年度股东大会的 致：辽宁何氏眼科医院集团股份有限公司 北京市中伦律师事务所（以下简称"本所"）接受辽宁何氏眼科医院集团股 份有限公司（以下简称"公司"）委托，指派本所律师对公司 2024 年年度股东大 会（以下简称"本次股东大会"）的合法性进行见证并出具法律意见。 本法律意见书根据《中华人民共和国公司法》（以下简称"《公司法》"）、 中国证券监督管理委员会（以下简称"中国证监会"）《上市公司股东会规则》 （以下简称"《股东会规则》"）等现行有效的法律、法规和规范性文件以及《辽 宁何氏眼科医院集团股份有限公司章程》（以下简称"《公司章程》"）的规定 而出具。 为出具本法律意见书，本所律师审查了公司本次股东大会的有关文件和材料。 本所律师得到公司如下保证，即其已提供了本所律师认为出具本法律意见书所必 需的材料，所提供的原始材料、副本、复印件等材料、口头证言均符合真实、准 确、完整的要求，有关副本、复印件材料与正本原始 ...

证券代码：301103 证券简称：何氏眼科 公告编号：2025-019 辽宁何氏眼科医院集团股份有限公司 2024 年年度股东大会决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 重要提示： 1.本次股东大会无增加、变更、否决提案的情况。 2.本次股东大会以现场与网络投票相结合的方式召开。 3.现场会议地点：辽宁省沈阳市皇姑区黄河南大街 118 号甲泰和国际大厦 15 楼会议室。 4.会议出席情况： 出席本次股东大会的股东及其股东代表均为 2025 年 5 月 16 日（星期五）下 一、会议召开和出席情况 辽宁何氏眼科医院集团股份有限公司（以下简称"公司"）2024 年年度股东 大会于 2025 年 5 月 22 日召开，公司董事会已于 2025 年 4 月 25 日在巨潮资讯网 上刊登了《关于召开 2024 年年度股东大会通知的公告》。 本次股东大会由公司董事会召集，现场会议由公司董事长何伟先生主持、召 开符合《公司法》、《上市公司股东大会规则》、《深圳证券交易所创业板股票上市 规则》及《公司章程》等规定。 1.会议召开方式：本次股东大会采用现场和网 ...

Core Insights - The collaboration between Carl Zeiss and He Eye Hospital marks the introduction of advanced refractive surgery technology in Northeast China, providing a revolutionary "10-second rapid vision correction" experience for myopic patients [1][3] - The new generation of all-laser technology, VISUMAX 800 and SMILE pro, offers significant improvements in surgical efficiency, precision, and safety, enhancing patient comfort during procedures [1][2] Group 1: Technology and Innovation - The VISUMAX 800 technology reduces single-eye scanning time from 23 seconds to under 10 seconds, improving efficiency by 36% and minimizing patient discomfort during surgery [1] - The technology features CentraLign intelligent navigation and OcuLign eye rotation compensation systems, which track eye movements in real-time and reduce postoperative residual astigmatism [1] - The dual robotic arm design ensures stable and reliable operation during surgery, enhancing overall safety [1] Group 2: Clinical Application and Experience - He Eye Hospital successfully completed its first SMILE pro surgery on May 15, with the first patient expressing high satisfaction with the quick and nearly painless procedure [2] - The hospital has established a comprehensive service management system, ensuring standardized operations and clinical experience to support the application of this breakthrough technology [2] - He Eye Hospital has been recognized as one of the first high-end refractive surgery institutions in China, emphasizing its commitment to technological innovation and patient-centered care [2] Group 3: Financial Services and Accessibility - The launch of the "Bright Future" financial service plan in collaboration with Industrial Bank provides low-interest installment credit services to myopic patients, making advanced technology more accessible [2]

Group 1 - The core viewpoint of the articles highlights the performance and financial metrics of He Shi Eye Hospital Group, indicating a recent stock price increase and a decline in shareholder numbers [1][2] - As of May 16, the closing stock price of He Shi Eye Hospital was 20.78 yuan, up by 1.02%, with a latest price-to-book ratio of 1.72, marking a new low in 13 days and a total market capitalization of 3.284 billion yuan [1] - The company reported a revenue of 291 million yuan for Q1 2025, representing a year-on-year increase of 2.35%, and a net profit of 32.53 million yuan, which is a 12.27% increase year-on-year, with a gross profit margin of 43.80% [1] Group 2 - The company has 9,399 shareholders as of March 31, 2025, a decrease of 392 shareholders from the previous count, with an average holding value of 352,800 yuan and an average shareholding of 27,600 shares [1] - He Shi Eye Hospital's main business focuses on personalized and intelligent eye health management services, including refractive surgery, cataract treatment, retinal disease treatment, and other eye disease treatments [1] - The company's price-to-earnings (P/E) ratio is significantly lower than the industry average, with a trailing P/E of -137.73 compared to the industry average of 37.33 [2]

Core Insights - The company aims to build a "Smart City of Light" focusing on global eye health, leveraging a comprehensive ecosystem in the eye health industry and utilizing technologies like big data, AI, and stem cells for digital and holistic eye health management [1][2] - The company has integrated digital technology and AI with public welfare, establishing a broad grassroots eye care service network, enhancing accessibility and inclusivity of eye health services, and contributing to rural revitalization [2] - The company emphasizes practical and applicable technology to improve healthcare service efficiency, aiming to make technological innovations beneficial to the public and promote global eye health [3] Summary by Sections Company Strategy - The company is focused on creating a comprehensive eye health management service model that encompasses the entire lifecycle of patient care, utilizing advanced technologies for precision and smart healthcare [1] Technological Integration - The company has developed the "Smart Eye Health Management Station" and "Light House" projects, which utilize AI for early detection and intervention of eye diseases, significantly improving public health service accessibility [2] International Collaboration - The company actively participates in international blindness prevention efforts, providing training for ophthalmologists in developing countries, thereby enhancing global eye health capabilities [2] Recognition and Awards - The "Light House" project received a gold award for service model innovation at the first national social medical "New Quality Productivity" case competition in 2024 [2]

Industry Rating - The industry investment rating is maintained at "Outperform the Market" [1] Core Insights - The medical services sector is under pressure in 2024 due to high base effects, but macroeconomic improvements are expected to drive a sustained recovery [2][5] - In Q1 2025, the demand for medical services has stabilized, leading to continuous profit improvement [3][5] - The gross profit margin has slightly declined, with 2024's margin at 37.02%, down 1.24 percentage points, and Q1 2025's margin at 36.14% [4][9] Summary by Sections 2024 Performance - The overall revenue for the medical services sector in 2024 is projected at 73.908 billion yuan, a year-on-year increase of 1.29% - The net profit attributable to shareholders is expected to be 4.857 billion yuan, a decrease of 16.37% - The net profit excluding non-recurring items is forecasted at 4.229 billion yuan, down 22.95% [2][9] Q1 2025 Performance - The total revenue for the medical services sector in Q1 2025 is 18.005 billion yuan, reflecting a year-on-year growth of 2.48% - The net profit attributable to shareholders is 1.325 billion yuan, showing a year-on-year increase of 16.24% - The net profit excluding non-recurring items is 1.266 billion yuan, up 18.21% [3][9] Profitability Metrics - The gross profit margin for 2024 is 37.02%, with a slight decline to 36.14% in Q1 2025 - The operating cash flow for Q1 2025 is 2.332 billion yuan, with a cash flow to net profit ratio of 158.22% [4][7]